BioCentury | May 12, 2014
Company News

Genea, Novogen deal

Novogen partnered with Genea's Genea Biocells Pty. Ltd. subsidiary to conduct preclinical testing of super-benzopyrans to treat degenerative diseases of the nervous system and muscles, including infantile neuraxonal dystrophy, fascioscapularhumeral dystrophy, amyotrophic lateral sclerosis (ALS),...
BioCentury | Oct 14, 2013
Finance

The VC spending gap

...DART) molecules; cancer stem cells; Fc antibody domain optimization Ph III $80M IPO in October NeurAxon Inc....
BioCentury | Jul 30, 2012
Company News

Infinity management update

...Mass. Business: Cancer, Inflammation Hired: Lawrence Bloch as EVP, CFO and CBO, formerly CEO of NeurAxon Inc. WIR...
BioCentury | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

...mucositis. nNOS/iNOS, a selective neuronal nitric oxide synthase 1 (NOS1; nNOS) and iNOS inhibitor from NeurAxon Inc....
BioCentury | Oct 6, 2011
Distillery Therapeutics

Indication: Neurology

...the nNOS inhibitors. NXN-188, a small molecule nNOS inhibitor and serotonin (5-HT) receptor agonist from NeurAxon Inc....
...for licensing from NeurAxon Contact: John S. Andrews, NeurAxon Inc., Mississauga, Ontario, Canada phone: 416-673-6697 e-mail: jandrews@neuraxon.com...
...published online Sept. 16, 2011; doi:10.1021/jm201063u Contact: Subhash C. Annedi, NeurAxon Inc., Mississauga, Ontario, Canada e-mail: sannedi@neuraxon.com BC...
BioCentury | Jun 20, 2011
Finance

Making the Milestone

...portfolio companies. Its most recent investments include $10 million in venture debt for neurology play NeurAxon Inc....
BioCentury | Nov 15, 2010
Clinical News

NXN-188: Phase II data

...events reported. Data were presented at the European Headache and Migraine Trust meeting in Nice. NeurAxon Inc....
BioCentury | Oct 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass. Business: Neurology Date completed: 9/29/10 Type: Venture financing Raised: $14 million Investors: CTI Life Sciences Fund; Ontario Capital Growth Corp.; Delphi Ventures; OrbiMed Advisors; Venture West; H.I.G. Ventures; BDC Venture Capital;...
BioCentury | Jan 4, 2010
Company News

NeurAxon board of directors update

NeurAxon Inc. , Waltham, Mass. Business: Neurology Appointed: Richard Meadows, managing director at CTI Life Sciences Fund L.P. WIR Staff...
BioCentury | Jan 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass. Business: Neurology Date completed: 12/29/09 Type: Venture financing Raised: $8.8 million Investors: CTI Life Sciences Fund; Delphi Ventures; OrbiMed Advisors; Ventures West; H.I.G. Ventures; BDC Venture Capital; NeuroVentures; company management Note:...
Items per page:
1 - 10 of 24
BioCentury | May 12, 2014
Company News

Genea, Novogen deal

Novogen partnered with Genea's Genea Biocells Pty. Ltd. subsidiary to conduct preclinical testing of super-benzopyrans to treat degenerative diseases of the nervous system and muscles, including infantile neuraxonal dystrophy, fascioscapularhumeral dystrophy, amyotrophic lateral sclerosis (ALS),...
BioCentury | Oct 14, 2013
Finance

The VC spending gap

...DART) molecules; cancer stem cells; Fc antibody domain optimization Ph III $80M IPO in October NeurAxon Inc....
BioCentury | Jul 30, 2012
Company News

Infinity management update

...Mass. Business: Cancer, Inflammation Hired: Lawrence Bloch as EVP, CFO and CBO, formerly CEO of NeurAxon Inc. WIR...
BioCentury | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

...mucositis. nNOS/iNOS, a selective neuronal nitric oxide synthase 1 (NOS1; nNOS) and iNOS inhibitor from NeurAxon Inc....
BioCentury | Oct 6, 2011
Distillery Therapeutics

Indication: Neurology

...the nNOS inhibitors. NXN-188, a small molecule nNOS inhibitor and serotonin (5-HT) receptor agonist from NeurAxon Inc....
...for licensing from NeurAxon Contact: John S. Andrews, NeurAxon Inc., Mississauga, Ontario, Canada phone: 416-673-6697 e-mail: jandrews@neuraxon.com...
...published online Sept. 16, 2011; doi:10.1021/jm201063u Contact: Subhash C. Annedi, NeurAxon Inc., Mississauga, Ontario, Canada e-mail: sannedi@neuraxon.com BC...
BioCentury | Jun 20, 2011
Finance

Making the Milestone

...portfolio companies. Its most recent investments include $10 million in venture debt for neurology play NeurAxon Inc....
BioCentury | Nov 15, 2010
Clinical News

NXN-188: Phase II data

...events reported. Data were presented at the European Headache and Migraine Trust meeting in Nice. NeurAxon Inc....
BioCentury | Oct 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass. Business: Neurology Date completed: 9/29/10 Type: Venture financing Raised: $14 million Investors: CTI Life Sciences Fund; Ontario Capital Growth Corp.; Delphi Ventures; OrbiMed Advisors; Venture West; H.I.G. Ventures; BDC Venture Capital;...
BioCentury | Jan 4, 2010
Company News

NeurAxon board of directors update

NeurAxon Inc. , Waltham, Mass. Business: Neurology Appointed: Richard Meadows, managing director at CTI Life Sciences Fund L.P. WIR Staff...
BioCentury | Jan 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass. Business: Neurology Date completed: 12/29/09 Type: Venture financing Raised: $8.8 million Investors: CTI Life Sciences Fund; Delphi Ventures; OrbiMed Advisors; Ventures West; H.I.G. Ventures; BDC Venture Capital; NeuroVentures; company management Note:...
Items per page:
1 - 10 of 24